Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q37622701

about

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Anticancer agent-based marine natural products and related compounds.Trabectedin for the treatment of breast cancer.A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.A drug development perspective on targeting tumor-associated myeloid cells.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects

P2860

Q33429467-B2FC0EED-465F-4262-9B08-9D7D95434323 Q36273796-1948870F-ECB9-43CC-BAB7-598A992B9A2B Q38307526-CE2D7135-5FC3-47D8-BF59-C520E7DEF6D2 Q38642314-331EA8D1-9667-457D-A68E-F22294931528 Q45024922-B16EF1AA-101D-4589-A5C7-FC35D8CC6175 Q48652546-56DB67C6-F9E0-4EF7-ACFE-2132FA983C98 Q55365628-0C4D5BA4-7B95-4B76-A853-FF395D64BDF5 Q57108205-1DA06AFF-1B8F-4CE2-ADE3-551B927FF745

P2860

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q37622701

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 September 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multicenter phase II study of ...... ion-resistant prostate cancer.

@en

Multicenter phase II study of ...... ion-resistant prostate cancer.

@nl

type

label

Multicenter phase II study of ...... ion-resistant prostate cancer.

@en

Multicenter phase II study of ...... ion-resistant prostate cancer.

@nl

prefLabel

Multicenter phase II study of ...... ion-resistant prostate cancer.

@en

Multicenter phase II study of ...... ion-resistant prostate cancer.

@nl

P1433

Q37622701-F414360B-FE89-4198-B56F-499AF8726C3D

P1476

Q37622701-39300E90-0026-449A-A719-C6A85D55C2F1

P2093

Q37622701-4ED25EA2-6E3A-40CD-BF00-BB894E25A0BD

Q37622701-622042CD-6615-4A52-A077-231626CE573C

Q37622701-8459FF23-58C8-4D1A-A58F-92E3A4ED24B6

Q37622701-8945E359-A308-433A-B9B9-2033A5217FF8

Q37622701-9D8DBFB7-66AE-4DE4-B46F-50C8B90A75B0

Q37622701-AEBA8230-E47A-4CB2-B552-B0237351768D

Q37622701-B2444350-8DD9-4C6B-8DEA-9DB0202BBDF1

Q37622701-C382EDF8-F02B-4BF6-8FFE-03A6C3360A59

Q37622701-C5CB5043-06E7-4932-B617-894BB0D072FD

Q37622701-CAF18BCD-C991-46C3-8CCB-8D8C9A4F76BC

P2860

Q37622701-0A01A458-9863-49DA-95D9-9595DD998EDA

Q37622701-178E4312-D4B0-48EF-A72A-4C6CFABAB185

Q37622701-28EA5E81-9802-4633-A314-AB2722842F08

Q37622701-331FD65F-5BDD-4EF8-BFF9-C3AC0FE9D2A3

Q37622701-44E26876-22C7-4FFE-8FCF-27B29E64300E

Q37622701-46951531-5CE0-4AA1-806F-ACC7BC00BAE9

Q37622701-63FE6600-FC3A-4398-878E-D4993C8CEBDD

Q37622701-7B022B8F-AA7B-421C-9FC4-135FA600DD57

Q37622701-7EE665EC-589C-4777-AA79-FBC96C2861B7

Q37622701-9DF631D3-C7D4-4D30-8DE2-25D8AA5E5089

P304

Q37622701-29E6F8BB-FD39-40E6-9DAE-7126EFA9CC29

P31

Q37622701-D036E2AB-DEEA-47CD-A990-AEB07E03674A

P356

Q37622701-B2729F13-5BDF-4FAC-88DD-334E9ADE2EB3

P433

Q37622701-F0CB255A-9A50-411F-B1E1-39C32D087E80

P478

Q37622701-54FCB451-314F-4D36-BDA6-286A38577DAE

P50

Q37622701-0EF5F1BE-AB69-42FE-B539-964D7E280C56

P577

Q37622701-6F53CBBC-C932-4EF7-BA10-7978A40BC44B

P698

Q37622701-86407861-163B-4215-951A-9AA16309652C

P921

Q37622701-B05387C4-F7BB-404E-B7AE-8E9422F7A6F7

P932

Q37622701-0B81C54B-6EAA-45CB-AA60-C3DE001BFA4D

P356

P1433

Annals of Oncology

P1476

Multicenter phase II study of ...... ion-resistant prostate cancer.

@en

P2093

A Nieto

http://www.w3.org/2001/XMLSchema#string

C A Stein

http://www.w3.org/2001/XMLSchema#string

C Kahatt

http://www.w3.org/2001/XMLSchema#string

G R Hudes

http://www.w3.org/2001/XMLSchema#string

I Pardos

http://www.w3.org/2001/XMLSchema#string

J Bellmunt

http://www.w3.org/2001/XMLSchema#string

M Cullell-Young

http://www.w3.org/2001/XMLSchema#string

M D Michaelson

http://www.w3.org/2001/XMLSchema#string

M R Smith

http://www.w3.org/2001/XMLSchema#string

N L Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Adding pharmacogenomics to the development of new marine-derived anticancer agents

Cancer statistics, 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Reporting results of cancer treatment

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

P304

1234-1240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDR399

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

P577

2011-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21930687

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3945398

http://www.w3.org/2001/XMLSchema#string